PMID- 35978041 OWN - NLM STAT- MEDLINE DCOM- 20220819 LR - 20231031 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 12 IP - 1 DP - 2022 Aug 17 TI - Network pharmacology combined with pharmacodynamics revealed the anti-inflammatory mechanism of Tanreqing capsule against acute-exacerbation chronic obstructive pulmonary disease. PG - 13967 LID - 10.1038/s41598-022-18326-1 [doi] LID - 13967 AB - Acute-exacerbation chronic obstructive pulmonary disease (AECOPD) is mainly associated with acute respiratory tract infection. In recent years, a growing number of studies have found that Tanreqing capsule (TRQ) has a favorable anti-inflammatory effect. In this study, we used network pharmacology and pharmacodynamics to explore the molecular mechanism and effects of TRQ in AECOPD treatment. To further understand the molecular mechanism of TRQ in AECOPD treatment, we used the network pharmacology to predict components of TRQ, TRQ-related targets, AECOPD-related targets, and pathways. In addition, we used the cigarette-smoke/lipopolysaccharide -induced AECOPD experimental model in Sprague-Dawley rats (72 rats randomly divided into six groups [n = 12 each]: control, model, high-TRQ [TRQ-H], medium-TRQ [TRQ-M], low-TRQ, and dexamethasone [Dex]) to evaluate the therapeutic effects of TRQ and to verify the network pharmacology. We found that 59 overlapping targets based on component-and AECOPD-related targets were frequently involved in the advanced glycation end product-receptor for advanced glycation end product signaling pathway in diabetic complications, the phosphatidylinositol-3-kinase-protein kinase B signaling pathway, and the hypoxia-inducible factor 1 signaling pathway, which might play important roles in the anti-inflammatory mechanism of TRQ in AECOPD treatment. Moreover, TRQ groups exerted protective effects against AECOPD by reducing the infiltration of inflammatory cells. Meanwhile, TRQ-M and TRQ-H groups significantly downregulated or upregulated the expression of tumor necrosis factor, interleukin (IL) 6, C-reactive protein, IL10, and serum amyloid A, as key targets in network pharmacology, in the serum and bronchoalveolar lavage fluid to achieve anti-inflammatory efficacy. Our study showed that TRQ had better anti-inflammatory efficacy against AECOPD, and initially elucidated its molecular mechanism. Moreover, our study also provides a new strategy to explore effective mechanism of TRQ against AECOPD; and further studies are needed to validate the biological processes and pathways of TRQ against AECOPD. CI - (c) 2022. The Author(s). FAU - Han, Xiao-Xiao AU - Han XX AD - College of Pharmacy, Henan University of Chinese Medicine, Zhengzhou, Henan, China. AD - Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases Co-Constructed by Henan Province and Education Ministry of P. R. China, Zhengzhou, 450046, Henan, China. FAU - Tian, Yan-Ge AU - Tian YG AD - Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou, Henan, China. AD - Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases Co-Constructed by Henan Province and Education Ministry of P. R. China, Zhengzhou, 450046, Henan, China. FAU - Liu, Xue-Fang AU - Liu XF AD - Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou, Henan, China. AD - Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases Co-Constructed by Henan Province and Education Ministry of P. R. China, Zhengzhou, 450046, Henan, China. FAU - Zhao, Di AU - Zhao D AD - Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou, Henan, China. AD - Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases Co-Constructed by Henan Province and Education Ministry of P. R. China, Zhengzhou, 450046, Henan, China. FAU - Du, Xue-Hang AU - Du XH AD - Shanghai Kaibao Pharmaceutical Co. Ltd, Shanghai, China. FAU - Dong, Hao-Ran AU - Dong HR AD - Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou, Henan, China. AD - Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases Co-Constructed by Henan Province and Education Ministry of P. R. China, Zhengzhou, 450046, Henan, China. FAU - Feng, Su-Xiang AU - Feng SX AD - Academy of Chinese Medical Sciences, Henan University of Chinese Medicine, Zhengzhou, Henan, China. fengsx221@163.com. AD - Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases Co-Constructed by Henan Province and Education Ministry of P. R. China, Zhengzhou, 450046, Henan, China. fengsx221@163.com. FAU - Li, Jian-Sheng AU - Li JS AD - Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases Co-Constructed by Henan Province and Education Ministry of P. R. China, Zhengzhou, 450046, Henan, China. li_js8@163.com. AD - The First Affiliated Hospital, Henan University of Chinese Medicine, Zhengzhou, Henan, China. li_js8@163.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220817 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (Anti-Inflammatory Agents) RN - 0 (Drugs, Chinese Herbal) RN - 0 (Interleukin-6) RN - 0 (tanreqing) SB - IM MH - Animals MH - Anti-Inflammatory Agents/pharmacology/therapeutic use MH - Drugs, Chinese Herbal MH - Interleukin-6 MH - *Network Pharmacology MH - *Pulmonary Disease, Chronic Obstructive/metabolism MH - Rats MH - Rats, Sprague-Dawley PMC - PMC9385617 COIS- The authors declare no competing interests. EDAT- 2022/08/18 06:00 MHDA- 2022/08/20 06:00 PMCR- 2022/08/17 CRDT- 2022/08/17 23:24 PHST- 2022/03/14 00:00 [received] PHST- 2022/08/09 00:00 [accepted] PHST- 2022/08/17 23:24 [entrez] PHST- 2022/08/18 06:00 [pubmed] PHST- 2022/08/20 06:00 [medline] PHST- 2022/08/17 00:00 [pmc-release] AID - 10.1038/s41598-022-18326-1 [pii] AID - 18326 [pii] AID - 10.1038/s41598-022-18326-1 [doi] PST - epublish SO - Sci Rep. 2022 Aug 17;12(1):13967. doi: 10.1038/s41598-022-18326-1.